HDAC9 and diffuse large B-cell lymphoma: Abexinostat, an oral pan-HDAC inhibitor, showed an ORR of 31% (CR in 6%) in 17 patients with relapsed/refractory DLBCL treated as part of a phase II trial of 100 patients with various types of NHL.